Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Recipients Of HIV/AIDS Programs Aid Expected To Feel Crunch Of Global Economic Crisis
At the 2009 HIV Implementers" Meeting in Namibia Thursday, Paul DeLay, deputy executive director of UNAIDS, said the global economic crisis will impact countries who receive international aid for HIV/AIDS programs, so recipients of such aid should identify priorities for their programs, the China Post reports (China Post, 6/12).
generic viagra online
Groups Mark Day Of The African Child, Highlight Improvement In Children's Survival, Work To Be Done
To mark Day of the African Child on Tuesday, the U.N. Millennium Campaign is calling on African governments, civil society organizations and the private sector to address child and maternal mortality and other targets related to the U.N. Millennium Development Goals (MDGs), InDepthNews reports (Mwanda, InDepthNews, 6/16), while Save the Children released a new briefing paper, indicating that more than 1,500 babies born in sub-Saharan Africa die daily, "mostly from preventable or treatable causes," (Save the Children release, 6/16).
News of the day
Link Between Low Levels Of Vitamin D And Common Vaginal Infection In Pregnant Women
Pregnant women with low levels of vitamin D may be more likely to suffer from bacterial vaginosis (BV) - a common vaginal infection that increases a woman"s risk for preterm delivery, according to a University of Pittsburgh study. Available online and published in the June issue of the Journal of Nutrition, the study may explain why African-American women, who often lack adequate vitamin D, are three times more likely than white women to develop BV.
Sexual Health

IFPMA Director General Michael D. Boyd's Remarks At WHO-UN Meeting With Vaccine CEOs

Mr Secretary General, Madame Director General, Ladies and Gentlemen, we are gathered here today in the shadow of the pandemic influenza threat posed by the Novel A / H1N1 virus. My name is Michael Boyd and I am Acting Director General of the International Federation of Pharmaceutical Manufacturers and Associations. I am speaking on behalf of the IFPMA Influenza Vaccine Supply international task force, which brings together sixteen of the leading research-based influenza vaccine manufacturers, from all five continents. We applaud the WHO for its leadership in addressing the H1N1 outbreak and welcome its efforts to strengthen collaboration with industry and to address the issues which have yet to be resolved. Clearly, we should do what we can to mitigate this threat. Given its potential scale, this will require a well-coordinated effort between multilateral organizations, governments around the world, public-private partnerships and industry. Our members are ready to produce an H1N1 pandemic vaccine when requested. They develop and produce most of the world"s seasonal influenza vaccine. They have also invested more than 4 billion US dollars over the last few years, both in pandemic vaccine research - to maximize the number of doses that can be made using existing capacity - and in building additional influenza vaccine production capacity. Developing a pandemic vaccine is a race against time. The WHO and the vaccine industry, in developed and developing countries alike, are working together closely to ensure rapid communication. The H1N1 outbreak shows that the WHO Global Influenza Surveillance Network works, making essential information and materials available to all manufacturers quickly and with a minimum of bureaucracy. Its rapid functioning is essential for a timely response to any pandemic threat and must not be compromised. The research-based vaccine and pharmaceutical industry is very conscious that countries differ widely in their level of economic development. Our members have voluntarily put in place a range of measures to help developing countries to access antiviral medicines and vaccines, including substantial donations to WHO stockpiles, tiered pricing adjusted to countries" ability to pay and voluntary licensing agreements with suitable local producers in developing countries. Some IFPMA member companies have also indicated to the WHO their readiness to reserve a portion of their vaccine manufacturing capacities for supply to developing countries. As Director General Chan recently said, the world has never been better prepared to face a possible pandemic. In part, at least, this is due to the combined efforts of the WHO and the vaccine industry represented by the IFPMA. Again, our companies stand ready to produce pandemic vaccines when requested and we are conscious of the need to provide access to developing countries, and are willing to work with other partners to help facilitate this. About the IFPMA The International Federation of Pharmaceutical Manufacturers & Associations is the global non-profit NGO representing the research-based pharmaceutical, biotech and vaccine sectors. Its members comprise leading international companies and national and regional industry associations covering developed and developing countries. International Federation of Pharmaceutical Manufacturers & Associations


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009